<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Bamias, A.</style></author><author><style face="normal" font="default" size="100%">Kyriakou, F.</style></author><author><style face="normal" font="default" size="100%">Chorti, M.</style></author><author><style face="normal" font="default" size="100%">Kavantzas, N.</style></author><author><style face="normal" font="default" size="100%">Noni, A.</style></author><author><style face="normal" font="default" size="100%">Kyroudi-Voulgari, A.</style></author><author><style face="normal" font="default" size="100%">Rontoyianni, D.</style></author><author><style face="normal" font="default" size="100%">Kastritis, E.</style></author><author><style face="normal" font="default" size="100%">Xiros, N.</style></author><author><style face="normal" font="default" size="100%">Patsouris, E.S.</style></author><author><style face="normal" font="default" size="100%">Murray, S.</style></author><author><style face="normal" font="default" size="100%">Tamvakis, N.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Microvessel density (MVD) and cyclooxygenase-2 (COX-2)/β-catenin interaction are associated with relapse in patients with transitional carcinoma receiving adjuvant chemotherapy with paclitaxel/carboplatin: A hellenic Cooperative Oncology Group (HECOG) st</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Bladder cancer</style></keyword><keyword><style  face="normal" font="default" size="100%">CD105</style></keyword><keyword><style  face="normal" font="default" size="100%">COX-2</style></keyword><keyword><style  face="normal" font="default" size="100%">MVD</style></keyword><keyword><style  face="normal" font="default" size="100%">β-Catenin</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-48849100188&amp;partnerID=40&amp;md5=3b3bd39cab6046ef7552419c912027fd</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">28</style></volume><pages><style face="normal" font="default" size="100%">2479 - 2486</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Background: Cycloxygenase (COX)-2 has been associated with proliferation, apoptosis and angiogenesis in urothelial cancer. The prognostic significance of COX-2 in patients who received adjuvant chemotherapy for urothelial cancer was examined. Patients and Methods: Expression of COX-2, p53, ki67, β-catenin, vascular endothelial growth factor (VEGF) and microvessel density (MVD) were studied retrospectively in 59 patients with urothelial cancer (pT3, pT4, N+) who had undergone surgery. The patients had subsequently received adjuvant chemotherapy. Results: Thirty-eight out of 59 cases (64% ) were positive for COX-2. COX-2 was not associated either with progression-free survival (PFS) or overall survival (OS). MVD levels ≥47 were associated with longer median PFS compared with lower levels (not reached vs. 13 months [95% CI: 8-18], p=0.048). The median PFS for patients with β-catenin nuclear accumulation and COX-2 expression was 6 months (95% CI: 4-7) compared with 19 months (95% CI: 14-23) for neither or only one of these factors (p=0.018). Conclusion: MVD may be a useful indicator of relapse in high-risk urothelial cancer treated with adjuvant chemotherapy.</style></abstract><issue><style face="normal" font="default" size="100%">4 C</style></issue><notes><style face="normal" font="default" size="100%">Cited By :7Export Date: 21 February 2017</style></notes></record></records></xml>